Ferumoxytol is a superparamagnetic iron oxide nanoparticle used off-label as an intravascular magnetic resonance imaging (MRI) contrast agent. Additionally, ferumoxytol-uptake by macrophages facilitates detection of inflammatory sites by MRI through ferumoxytol-induced image contrast changes. Therefore, ferumoxytol-enhanced MRI holds great potential for assessing vascular function and inflammatory response, critical to determine placental health in pregnancy. This study sought to assess the fetoplacental unit and selected maternal tissues, pregnancy outcomes, and fetal well-being after ferumoxytol administration. In initial developmental studies, seven pregnant rhesus macaques were imaged with or without ferumoxytol administration. Pregnancies went to term with vaginal delivery and infants showed normal growth rates compared to control animals born the same year that did not undergo MRI. To determine the impact of ferumoxytol on the maternal-fetal interface (MFI), fetal well-being, and pregnancy outcome, four pregnant rhesus macaques at ∼100 gestational day underwent MRI before and after ferumoxytol administration. Collection of the fetoplacental unit and selected maternal tissues was performed 2-3 days following ferumoxytol administration. A control group that did not receive ferumoxytol or MRI was used for comparison. Iron levels in fetal and MFI tissues did not differ between groups, Ferumoxytol MRI in rhesus macaque pregnancy, 2020, Vol. 102, No. 2 435 and there was no significant difference in tissue histopathology with or without exposure to ferumoxytol, and no effect on placental hormone secretion. Together, these results suggest that the use of ferumoxytol and MRI in pregnant rhesus macaques does not negatively impact the MFI and can be a valuable experimental tool in research with this important animal model.
Introduction
In the hemochorial human and non-human primate placenta, maternal intervillous blood bathes the placental villi, allowing oxygen and nutrient transfer to the fetal blood circulating within the capillaries of the villous stroma. Pregnancy complications may stem from maladaptation of maternal vessels causing insufficient placental perfusion, leading to macrophage recruitment, cytokine release, and hypoxia at the maternal-fetal interface (MFI). Compromised intervillous flow is associated with adverse pregnancy outcomes [1] [2] [3] [4] : insufficient placental perfusion could result in fetal growth restriction, preeclampsia, and pregnancy loss. The ability to identify abnormal uteroplacental vascular adaptation, compromised perfusion, and attendant inflammation could be valuable in identifying at-risk pregnancies before clinical manifestations.
Currently, ultrasound is the most commonly used method to assess fetal growth. It is also used to detect umbilical and uteroplacental blood flow abnormalities, but only indirectly through velocity waveform analysis. Further, ultrasound lacks the ability to detect immune cell homing to the MFI that may precede adverse pregnancy outcomes. Magnetic resonance imaging (MRI) can provide high-resolution anatomic and functional information including blood velocities and flow, perfusion, and oxygenation to characterize placental implantation site, visualize maternal pelvic structures, and diagnose abnormally aggressive trophoblast invasion or placental abruption [5] . In many clinical applications, gadoliniumbased contrast agents (GBCAs) are used to quantify tissue perfusion and perform high-resolution angiography [6] . In the non-human primate, gadolinium MRI has been used to investigate spiral artery and perfusion domain (cotyledon) location, and quantify placental perfusion [7, 8] , the latter of which has also been achieved in humans [9] . However, GBCAs have been shown to cross the placenta into the fetus with uncertainty in the long-term consequences of in utero GBCA exposure [10] . Although there is no specific evidence that it causes teratogenic or chromosomal damage [11] [12] [13] , the risk to the fetus of gadolinium-based MR contrast agent administration remains unknown and should not be routinely provided to pregnant patients [14] .
In this study, we explored an alternative approach for quantitative tissue perfusion and MR angiography in pregnancy, using the superparamagnetic iron oxide nanoparticle (SPION) ferumoxytol as a contrast agent. Ferumoxytol is approved by the Federal Drug Administration (FDA) for the treatment of anemia in adults with renal insufficiency and for iron deficiency anemias refractory to oral iron therapy [15] . It is considered to be safe and effective for treatment of iron deficiency anemia refractory to oral iron therapy in pregnant women [16] . Ferumoxytol has also emerged as an off-label MR contrast agent at a much lower dose than is used therapeutically for anemia. Ferumoxytol has favorable MR properties [17, 18] that can yield high-detail angiography and functional information about the MFI non-invasively, including quantitative perfusion maps of maternal blood that allow for analysis of individual cotyledons in the placenta [19] , as seen in imaging with gadolinium [7] . As such, it has high potential to identify local and global perfusion abnormalities that might be indicative of placenta pathologies. Ferumoxytol also has the potential to spatially localize inflammatory events, as the nanoparticles are taken up by activated cells of the mononuclear phagocyte system at sites of tissue inflammation, which can then be imaged after ferumoxytol in the blood space has cleared [17, [20] [21] [22] [23] [24] . The MRI transverse relaxation rate R2 * has a relationship with the concentration of iron in tissue. Therefore, R2 * mapping may enable localization of iron-laden macrophages, as well as quantification of their density. Ferumoxytol's safety profile and properties for MR imaging make it a promising contrast agent to address the unmet need for non-invasive diagnosis of placental health with potential for clinical routine use. Importantly, demonstrating its use for placental imaging is a necessary step in this application. Therefore, the purpose of this work was to assess the feasibility of ferumoxytol imaging and the impact of administration on the MFI, fetal well-being, and pregnancy outcomes in a non-human primate model. The rhesus macaque provides an accurate experimental model of the human MFI and immune system, having hemochorial placentation, endovascular trophoblast invasion with attendant spiral artery remodeling, and chorionic villous placental architecture.
Materials and methods

Ethics statement
This study was approved by the University of Wisconsin-Madison Graduate School Institutional Animal Care and Use Committee. Twelve pregnant macaques in the WNPRC breeding colony were used for peripheral blood mononuclear cell (PBMC) experiments, placentas from six macaques from unrelated projects were used for placenta explant experiments, four pregnant macaques were imaged by MRI without ferumoxytol, and seven pregnant macaques were imaged by MRI with ferumoxytol, four of which ended in fetectomy. An additional four pregnant macaques went to fetectomy without imaging.
Care and use of macaques
Female rhesus macaques in the Wisconsin National Primate Center (WNPRC) breeding colony were housed with compatible males and monitored for breeding and menses. Pregnancies were confirmed and dated (+/−2 days) based on menstrual cycle, observation of copulation, and ultrasound measurements of gestational sac and fetuses. Blood samples were collected using a needle and syringe or vacutainer system from the femoral or saphenous vein. All infants born from this study (i.e., were not taken by fetectomy) joined the WNPRC colony. All macaques were cared for by WNPRC staff in accordance with the regulations and guidelines outlined in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals. All animals including infants born from pregnancies that received MRI are systematically monitored twice daily by WNPRC staff and veterinarians, and additionally as needed. All irregular observations are immediately entered into the colony electronic health records. Observations may include the presence of blood, trauma, irregular feces, variation in eating patterns, lethargy, vomit, abnormal behavior including self-injury, evidence of breeding behavior, and infant nursing.
Immune cell isolation and incubation with ferumoxytol
Monocytes and macrophages for in vitro ferumoxytol-uptake studies were isolated from whole blood drawn from 12 pregnant rhesus macaques, at ∼100 gestational day (GD) (term = 165GD), as previously reported [25] . Neutrophils were isolated as previously published [26] . All three cell types were incubated in ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA) at 0, 50, 100, or 200 μg/ml for 1 h. Additionally, there were incubations of 0 or 200 μg/ml with activating agents (50 ng/ml phorbol-12myristate-13-acetate (PMA; Sigma-Aldrich, St. Louis, MO)) for all cell types, 750 ng/ml ionomycin (Sigma-Aldrich, St. Louis, MO) for monocytes only). Following incubation, cells were washed and fixed with 2% paraformaldehyde (PFA) for visualization of iron content by Prussian blue staining [27] [28] [29] . Cells were imaged using a Nikon Eclipse TE300 microscope with NIS-Elements image capture.
Placental explant incubations in ferumoxytol
Prior to imaging experiments, placental explants were prepared from tissues obtained from untreated animals undergoing fetectomy or cesarean section in unrelated studies, during first trimester of pregnancy (n = 2) or at term (n = 4). Explants were incubated in ferumoxytol at 0, 100, or 200 μg/ml, diluted in DMEM/F12 with 10% fetal calf serum, for 2, 4, and 24 h at 37 • C in room air/5% CO 2 . Explants were fixed in 2% PFA overnight and embedded in paraffin blocks. Tissues were imaged using a Nikon Eclipse TE300 microscope with NIS-Elements image capture.
Prussian blue staining
To visualize cellular iron content, isolated, fixed immune cells grown on coverslips or deparaffinized rehydrated tissue sections were incubated in Prussian blue solution [27] [28] [29] for 20 min, washed with deionized water, and mounted with Aquapolymount (Polysciences, Warrington, PA).
MRI impact on pregnancy outcome and postnatal growth
There were two imaging phases in this study. In the first phase ( Figure 1A ), seven pregnant macaques were imaged, three with ferumoxytol and four without, to establish standard methods for anesthesia and imaging, and to pilot scan settings. These pregnancies went to term after imaging for spontaneous delivery. Animals that did not receive ferumoxytol had a single imaging session and were completed first to determine feasibility and ascertain appropriate imaging sequences prior to the addition of contrast agent. Animals that received ferumoxytol also had four non-ferumoxytol follow-up imaging sessions at ∼1 day, 1, 2, and 3 weeks post-ferumoxytol. Infants joined the WNPRC colony and weights of infants exposed to MRI with or without ferumoxytol in-utero were compared to 116 untreated WNPRC 2016 colony infants through their first year of life. Mean and standard deviation weights for untreated colony infants were calculated at different ages, similar to the approach previously published [30] . These experiments were completed before moving to the second phase of the study.
Use of IL-1beta to induce MFI inflammation
In the second phase ( Figure 1B ), we used a paradigm of ferumoxytol MRI following intra-amniotic injection of 10 mg human recombinant IL-1β (PeproTech, Rocky Hill, NJ) in 0.5 ml sterile saline (n = 4). This paradigm has been reported previously to increase decidual macrophage numbers and model chorioamnionitis and preterm labor [31, 32] or sterile saline (n = 4), and we used it to test the efficacy of ferumoxytol detection of mononuclear phagocytes and inflammation [17, [20] [21] [22] [23] [24] at the MFI. At ∼100GD, both saline and IL-1β animals received a baseline MRI without ferumoxytol on day 1, MRI with ferumoxytol on day 2, and follow-up nonferumoxytol MRIs on days 3 and 4. Untreated controls (n = 4) did not receive intra-amniotic injections, ferumoxytol, or MRI. While the resulting R2 * maps of the MFI from IL-1β-exposed animals did not differ from those of animals receiving intra-amniotic saline [34] , comparison of saline-injected and untreated animals allows determination of any impact of ferumoxytol MRI at the MFI or on the fetus. The results of the IL-1β-exposed animals will not be discussed in this report.
Intra-amniotic injection
Procedures were performed under transabdominal ultrasound guidance on the lateral aspect of the abdomen. A syringe filled with sterile saline was attached to a biopsy needle and inserted through an aseptically prepared site of the abdominal wall until the tip reached the wall of the uterus, avoiding the bowel and bladder (n = 4, Figure 1B ). The needle was advanced into the amniotic cavity and a small amount of amniotic fluid was drawn to confirm needle placement. The contents of the syringe were then slowly injected into the amniotic cavity, and the needle was withdrawn. Following withdrawal of the needle, the insertion site in the uterus was observed by ultrasound to confirm lack of bleeding.
Magnetic resonance imaging
A total of 11 monkeys were imaged for the current study, seven with ferumoxytol. Experiments took place between January 2016 and April 2018. All animals that underwent an MRI exam, regardless of whether they also received ferumoxytol, were sedated by injection of up to 10 mg/kg ketamine, intubated, and anesthesia was maintained by inhalation of oxygen and 1.5% isoflurane. A pulse oximeter probe was placed and vital signs were monitored every 15 min. Animals were imaged in the right-lateral position and a respiratory bellow was placed around the animal's belly during imaging to enable respiratory-compensated imaging that minimizes motion-related artifacts. Animals that received ferumoxytol had an intravenous catheter placed for injection during imaging.
For scans with ferumoxytol, dynamic contrast enhanced (DCE) images were acquired on a clinical 3.0 T MRI system (Discovery MR750, GE Healthcare, Waukesha, WI) utilizing a 32-channel torso radiofrequency coil (Neocoil, Pewaukee, WI). Time resolved T1weighted DCE images with 5 s temporal resolution were obtained throughout the ferumoxytol administration [33] . Scanner time for animals that did not undergo DCE scanning, including animal setup in the magnet and all time between scans, ranged from 1.5 to 2.5 h. Animals that underwent DCE scanning had times ranging from 2 to 4.5 h to do pre-and post-ferumoxytol imaging and calibrations required for DCE. Ferumoxytol diluted 5:1 with normal saline was administered at 4 mg/kg body weight over a 20 s interval using a power injector, followed by a 20 ml saline flush at the same rate. A baseline R2 * MRI scan (an MRI relaxation parameter highly correlated and sensitive to detect iron concentration) was performed before ferumoxytol administration. R2 * measurements were estimated in the maternal, MFI, and fetal tissues by region-ofinterest analysis directly from the MRI images. Follow-up R2 * MRI scans were performed on subsequent days after contrast injection to determine the persistence of ferumoxytol in various tissues. MRI acquisition parameter details can be found elsewhere [33, 34] .
Assessment of maternal clinical outcomes with ferumoxytol administration
Additional to the seven animals in this study that received MRI with ferumoxytol, one time each, there are several studies not discussed here being completed that also utilize ferumoxytol MRI. Within these studies, there are 28 animals that have received MRI with ferumoxytol up to three times, at the same dose discussed here per imaging session. The seven animals in our current study and these additional 28 animals are considered together to estimate the frequency of potential acute allergic reaction to ferumoxytol. No other information for these additional 28 animals will be considered in this report.
Fetectomy
At ∼100GD, the fetoplacental unit was collected via hysterotomy (n = 8, Figure 1B ). Maternal biopsies were collected aseptically during surgery and the dam recovered. The fetus was euthanized by intravenous or intracardiac injection of 50 mg/kg sodium pentobarbital. Fetal and MFI tissues were dissected for histology, iron content mass spectrometry, and protein assay.
Tissue homogenates
Tissues collected at fetectomy (0.1-0.7 g) (Supplemental Data S1) were homogenized in a Bullet Blender (Next Advance, Troy, NY) at full power for 10 min with non-metal blending beads and 500 μl PBS. Tissue homogenate was stored at −80 • C until use. A 96well format micro bicinchoninic acid (BCA) protein assay (Thermo Scientific, 23235) was used to determine protein concentrations in homogenates assayed for iron content according to the manufacturer's instructions.
Iron content determinations
Tissue homogenates were assayed for iron concentrations at the Wisconsin State Laboratory of Hygiene Trace Element Research Group in selected maternal, fetal, and MFI tissues via inductively coupled plasma-optical emission spectrometry [35] [36] [37] [38] . The limit of detection is 1 μg/g tissue.
Steroid hormone extraction and LC/MS/MS analysis
Maternal plasma samples (450 μl) collected for multi-steroid analysis from animals that had tissues collected at fetectomy ( Figure 1B) were extracted and assayed as previously reported [39, 40] . The limit of detection is 30 pg/ml for progesterone; 6 pg/ml for estrone and estradiol.
Histology
Tissues collected for histology were fixed in 4% PFA overnight, 70% ethanol overnight, and routinely processed and embedded in paraffin. About 5 μm sections were stained with H&E and assessed by veterinary pathologists blinded to treatment groups. Tissues were evaluated for the presence or absence of physiologically significant pathologic changes, normal anatomic variations, and inflammation. Morphologic diagnoses (Supplemental Data S2) summarize these histologic findings. Organs not given a morphologic diagnosis are considered to have no significant pathologic or inflammatory changes and were scored as a 0. Severity (none = 0, minimal = 1, mild = 2, moderate = 3, severe = 4) was determined by the extent and distribution of inflammation, vascular change (infarction, thrombosis, pregnancy associated vascular remodeling, and/or the lack thereof), and non-vascular necrosis across the tissue section or organ (multiple slides were necessary to evaluate the placenta). Scores were averaged and compared between treatment groups as previously reported [41] . Some MFI tissue sections were stained with Prussian blue for iron localization.
Statistics
Iron concentrations in tissue homogenates were compared between treatment groups by 2-way ANOVA and Sidak's multiple comparison test. Differences in pathology and changes in R2 * values were assessed by 2-way ANOVA. Hormone level changes were assessed by 1-way ANOVA.
Results
PBMC incubations
To determine whether rhesus macaque cells take up ferumoxytol as reported with human cells [17, [20] [21] [22] [23] [24] , prior to initiating the imaging phases of this study, rhesus monocytes, macrophages, and neutrophils were incubated in 100 μg/ml ferumoxytol (Supplemental Figure S1 ), the approximate concentration of ferumoxytol in the blood with administration for MRI, and iron was visualized by Prussian blue staining. Staining was seen in differentiated macrophages but not monocytes or neutrophils. Activation with PMA and ionomycin did not affect iron staining. No staining was seen without ferumoxytol incubation.
Placental explants incubations
To determine whether placental ferumoxytol uptake by placental tissue may confound use for inflammation mapping in vivo, prior to initiating the imaging phases of this study, rhesus placental explants were incubated with ferumoxytol and stained with Prussian blue. Modest background Prussian blue iron staining in tissue was observed independent of ferumoxytol incubation, likely indicating endogenous iron content (Supplemental Figure S2 ). Minimal increase in iron staining was observed after 2 h of ferumoxytol-incubation. An increase in iron staining appeared after 24 h incubation, specifically in the villous endothelium of the placental tissue. Not substantial staining of the syncytiotrophoblasts was observed, the primary interface exposed to ferumoxytol in maternal blood in vivo. Low levels of endogenous iron and modest increases in ferumoxytol uptake in control placental explants ex vivo after incubations suggests that in vivo inflammation detection by ferumoxytolenhanced MRI would be feasible and not confounded by background placental iron content/uptake.
Maternal clinical outcomes with ferumoxytol administration
In addition to the seven animals in this study that received ferumoxytol for MRI (Figure 1 ), 28 pregnant rhesus monkeys from other ongoing studies (unpublished) had up to three ferumoxytol imaging sessions. In 35 total experimental subjects who had ferumoxytol imaging sessions, two animals required moderate medical attention following ferumoxytol administration. Both animals had periocular edema following IV bolus administration of ferumoxytol that was treated with 10 mg diphenhydramine hydrochloride. One animal had a short period of increased heart rate and SPO2 levels. This animal had previous ocular swelling not associated with ferumoxytol, so it is unclear whether this event was due to ferumoxytol or other drugs used to anesthetize the animal. These mild allergic reactions responded to diphenhydramine and the animals recovered without further medical intervention.
Pregnancy outcomes
Seven pregnant rhesus macaques ( Figure 1A ) who underwent MRI gave birth via vaginal delivery at term, and the infants joined the WNPRC colony. Results of these imaging studies are described in separate reports [33, 42] . Pregnancy outcomes were generally unremarkable, with one retained placenta (which occurs in ∼2.6% of WNPRC pregnancies). None of the seven dams had immediate or long-term reactions to the ferumoxytol treatment.
Infant growth data from these pregnancies are plotted along with their birth year cohort weights ( Figure 2) . The weights of the MRI offspring generally stayed within one standard deviation of the average infant weights. Infants followed normal physiological and sociobehavioral patterns seen in other colony infants as assessed by daily veterinary observations.
Ferumoxytol detection by MRI following administration
Three of the seven pregnant rhesus macaques that carried infants to term ( Figure 1A ) had been imaged with ferumoxytol at ∼100GD. Imaging occurred immediately before (to establish a baseline R2 * values in maternal, MFI, and fetal tissue) and 15 min after administration of ferumoxytol, followed by four follow-up MRI scans at ∼1 day, 1, 2, and 3 weeks following ferumoxytol administration. In all three animals, an increase in R2 * values in both the primary and secondary placental disks is seen immediately following ferumoxytol injection (Figure 3) . The R2 * values in fetal lung remained close to baseline though all scans while fetal liver R2 * values increased slightly in two of the three animals. This may reflect an increase in physiological iron transport to the fetus over time in normal pregnancy, unrelated to ferumoxytol. The R2 * values in the placenta, which increased dramatically following ferumoxytol administration, returned to approximate baseline levels within 1 day postferumoxytol, supporting a rapid clearance of ferumoxytol from the blood. Ferumoxytol accumulation in the placenta or transfer to the fetus was not detectable by R2 * [34] .
Iron content in tissues
Maternal, MFI, and fetal tissues from eight pregnancies ( Figure 1B) were surgically collected at ∼100GD following MRI and iron concentrations were determined in these tissues (Figure 4) . When ferumoxytol-exposed and untreated control groups were compared, only maternal liver showed a significant increase in iron concentration with maternal ferumoxytol administration over control (P < 0.0001). There are no significant differences in fetal tissue iron levels in ferumoxytol vs. non-ferumoxytol-exposed animals.
Prussian blue staining of MFI tissues
Prussian blue staining varied animal-to-animal in the placenta, decidua, and fetal membranes from animals that underwent fetectomy. Tissues from ferumoxytol-receiving animals, overall, did not have noticeably different staining compared to non-ferumoxytolreceiving animals. Interestingly, the animal with the most consistent staining had not received ferumoxytol (Supplemental Figure S3 ), likely reflecting normal physiological iron.
Ferumoxytol effects on plasma progesterone, estrone, and estradiol
For each imaging day in animals that underwent fetectomy ( Figure 1B) , maternal plasma samples were assessed by mass spectrometry for progesterone, estrone, and estradiol levels [39, 40] to assess the impact of MRI imaging and ferumoxytol administration on placental endocrine function. Non-imaged controls ( Figure 1B) received a one-time plasma-collection at time of fetectomy. There was no statistically significant change in placental hormone levels following administration of ferumoxytol and hormone levels generally stayed within the range of levels seen in non-imaged controls ( Figure 5 ).
Ferumoxytol effects on histopathology
Of 37 maternal and fetal tissues collected at fetectomy (Supplemental Data S1), the placenta, decidua, amniotic membranes, placental bed, maternal spleen, and maternal liver had notable histopathology. Animals that did and did not receive ferumoxytol MRI had no statistically significant differences in individual tissue histopathology scores ( Figure 6 ). Morphologic diagnoses are provided in Supplemental Data S2.
Discussion
In this study, we examined the impact of MRI with and without ferumoxytol on the fetoplacental and maternal tissues, pregnancy outcomes, and fetal well-being in the pregnant rhesus macaque. Offspring from imaged pregnancies with or without ferumoxytol had uneventful labor and normal growth in comparison with contemporary pregnancies from the WNPRC breeding colony. No significant impact of MRI with ferumoxytol on iron content or histopathology of fetal and MFI tissues (decidua, placenta, fetal membranes) was observed. Placental function as indicated by peripheral blood steroid hormone levels was unaffected by MRI with ferumoxytol. The lack of significant adverse outcomes in the rhesus subjects also suggests the utility of ferumoxytol as a non-gadolinium contrast agent for MRI in pregnancy studies.
In vitro culture experiments demonstrated that ferumoxytol was taken up by macrophages differentiated from peripheral blood monocytes, but not by undifferentiated monocytes or granulocytes. This indicates that ferumoxytol is a feasible reagent to detect the accumulation of phagocytic macrophages at sites of inflammation. Tissue macrophages take up ferumoxytol and clear these iron nanoparticles more slowly than those in the blood, therefore, sites of inflammation can be located by performing delayed imaging following ferumoxytol administration. This paradigm may help identify inflammation at the MFI, which could predict an insult to the pregnancy.
Concerns about ferumoxytol uptake by the placenta and the potential for transport of elevated levels of iron to the fetus, putting the fetus at risk for hemochromatosis or pulmonary hemosiderosis since these disorders result in fetal growth restriction, hepatic failure, alveolar hemorrhage, and stillbirth [43] [44] [45] were addressed. Placental villous explants were incubated in vitro with physiologically relevant concentrations of ferumoxytol, and staining of explant tissue sections for iron content with Prussian blue did not demonstrate any significant uptake of SPION by placental tissues in a physiologically meaningful pattern (i.e., syncytiotrophoblast uptake) that would be anticipated with exposure of the placenta to ferumoxytol in the maternal blood in the intervillous space.
The fetus acquires iron during pregnancy through transferrin receptor acquisition of ferritin and transit across the placental syncytiotrophoblast and cytotrophoblast to the fetal vasculature within villous stroma [46] . Placental tissues collected from MRI experiments and stained with Prussian blue for iron content did not reveal discernible differences between tissues from control and ferumoxytol-treated pregnancies. Additionally, decidual tissues and fetal membranes did not demonstrate any consistent differences between experimental groups. There were focally distributed areas of iron detected by Prussian blue staining, however interestingly, the tissues with the clearest demonstration of iron content were the decidua and fetal membranes rather than the placental villi. It is important to note that the animal in which iron was most readily demonstrated in these tissues did not receive ferumoxytol and thus SPION-delivered iron was not the source of Prussian blue staining. These data suggest that although the placenta directly transports iron to the fetus via a biologically conserved ferritin/ferritin receptor-mediated pathway, this active pathway does not participate in the uptake of ferumoxytol by the syncytiotrophoblasts. We hypothesize that cellular iron sequestration, as indicated by Prussian blue staining, may be largely attributable to macrophage uptake of erythrocytes as a routine surveillance function at the MFI. Consistent with a lack of increase in iron content of MFI tissues by histochemical methods, there was no significant increase in iron concentration in MFI tissues by mass spectrometry. Likewise, fetal tissues that would be anticipated to accumulate iron did not show a statistically significant increase. While there does appear to be a trend for slightly higher, though not statistically significant, iron content in fetal tissues, further studies will be needed to determine if this is a consistent result. There was a statistically significant increase in maternal liver iron content, which was expected since the liver is a main clearance organ for ferumoxytol, with resident hepatic macrophages (Kupffer cells) taking up ferumoxytol particles in studies in rabbit [47] and human subjects [48, 49] .
Histopathology was evaluated in selected maternal tissues, the MFI, and in fetal tissues. There was no detectable histopathology in any fetal tissues. While histopathology was noted in tissues at the MFI, there were not significant differences between ferumoxytolreceiving and control animals. Some histopathological features were noted among placentas even in untreated "normal" pregnancies. Functional assessment of the placenta by monitoring of placental hormone secretion (progesterone, estradiol, estrone) likewise revealed no significant difference between animals receiving ferumoxytol MRI imaging, and untreated animals.
The use of an animal model to evaluate MRI methodologies has significant advantages. The pregnant dam is anesthetized for the imaging procedure in the non-human primate model, and the inhaled anesthetic is transferred to the fetus, which is also anesthetized. Therefore, the fetal motion is minimized in MRI of the animals, leading to reliable MRI results. However, anesthesia is not the standard of care for MRI evaluation of pregnant humans and the potential fetal motion in MRI of pregnant human subjects will need to be addressed. A motion-robust R2 * mapping technique has been proposed by our group and showed to effectively diminish motion effects in human scans [34] . Upon successful validation, the motionrobust MRI technique may enable detection of macrophage homing in pregnant women. It should also be noted that ferumoxytol was injected as a diluted bolus in our current macaque study, while it is administered as a slow infusion in humans to reduce the risk of anaphylactic reactions.
In summary, we conclude that ferumoxytol administration for imaging in this rhesus pregnancy model is feasible. Ferumoxytol effects on the fetus were minimal in this study with evidence that the SPION may not cross the placenta. Future studies will explore the use of ferumoxytol to detect placental inflammation and the diagnostic value of DCE MRI in the presence of placental dysfunction. The rhesus macaque will be an important platform for initial development of novel imaging approaches in an experimentally tractable model.
